Nature Research has republished an in-depth article on Vect-Horus in the September issue of Biopharma Dealmakers. The issue focuses on CNS related technologies and therapeutics.
It’s well worth having a read, or re-read, of this piece, which outlines our VECTrans platform and its potential to transform the treatment of neurodegenerative disorders.
It also touches on the science and data behind our approach and our partnerships with Novo Nordisk Radiomedix, Inc. and Ionis Pharmaceuticals, Inc.